| Can intravascular ultrasound guidance modify the efficacy of drug-eluting stent over bare-metal stent in an aorto-ostial lesion? | |
| | |
MedLine Citation:
|
PMID: 21421189 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
PURPOSE: We compared the efficacy of drug-eluting stents (DESs) versus bare-metal stents (BMSs) in de novo and native aorto-ostial lesions (AOLs) guided by intravascular ultrasound (IVUS). METHOD: Thirty-eight patients underwent DES implantation for 38 AOLs; 35 with sirolimus-eluting stents, and three with paclitaxel-eluting stents (DES group). The control group was composed of 40 AOLs treated by BMS. The incidence of the primary composite end point of all-cause mortality, Q-wave myocardial infarction and target vessel revascularization (TVR) as TVR-major adverse cardiac event (TVR-MACE) was evaluated during a 1-year follow-up. Clinical and IVUS parameters were compared between the DES and BMS groups, and Cox hazards model was used to calculate hazard ratios of several factors for the 1-year TVR-MACE. RESULTS: Although the vessel, plaque, and stent volumes were significantly larger after the procedures in the DES group owing to longer lesions (18.3±5.1 vs. 13.2±5.9 mm, P<.001), the stent volume index (10.8±2.6 vs. 12.4±3.3, P=.024) was much smaller than that in the BMS group. During the 1-year follow-up, there were 13 TVR-MACEs in all patients (13% in DES vs. 20% in BMS, P=.4 by Kaplan-Meier analysis). The Cox hazards model did not indicate any specific unfavorable factor for the 1-year TVR-MACE. CONCLUSIONS: The present study showed equality between DES and BMS on de novo and native AOLs about the 1-year TVR-MACE rate, even though a DES was used in longer and bulkier lesions as compared to BMS. |
| | |
Authors:
|
Teruo Okabe; Akio Kawamura; Yuichiro Maekawa; Toshihisa Anzai; Shiro Iwanaga; Tsutomu Yoshikawa; Satoshi Ogawa |
Related Documents
:
|
21272979 - Hospital universiti sains malaysia experience in orbital floor reconstruction: autogeno... 15709899 - Tolcapone in parkinson's disease: liver toxicity and clinical efficacy. 20927559 - Cardiac ¹²³i-mibg scintigraphy as an outcome-predicting tool for subthalamic nucleus... 21161419 - Physician groups' use of data from patient experience surveys. 21414749 - Femoral revision in hip resurfacing compared with large-bearing metal-on-metal hip arth... 21199119 - Efficacy of different concentrations of sevoflurane administered through a face mask fo... 16226179 - Operative and late coronary artery bypass grafting outcomes in matched african-american... 7223809 - Laser photovaporization of endometrium for the treatment of menorrhagia. 1345799 - Mortality in patients with the acquired immunodeficiency syndrome treated with either f... |
Publication Detail:
|
Type: Journal Article Date: 2010-10-20 |
Journal Detail:
|
Title: Cardiovascular revascularization medicine : including molecular interventions Volume: 12 ISSN: 1878-0938 ISO Abbreviation: Cardiovasc Revasc Med Publication Date: 2011 Mar-Apr |
Date Detail:
|
Created Date: 2011-03-22 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101238551 Medline TA: Cardiovasc Revasc Med Country: United States |
Other Details:
|
Languages: eng Pagination: 105-10 Citation Subset: IM |
Copyright Information:
|
Copyright © 2011 Elsevier Inc. All rights reserved. |
Affiliation:
|
Cardiology Department, International University of Health and Welfare, Mita Hospital, Tokyo, Japan. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Contemporary approaches to perioperative management of coronary stents and to preoperative coronary ...
Next Document: Cardiovascular magnetic resonance imaging in delivering and evaluating the efficacy of hepatocyte gr...